Get the Stockscreener App
14.27
0.63%
-0.09
Abrdn Life Sciences Investors Stock (HQL) Forecast
The Abrdn Life Sciences Investors (HQL) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $10.64, representing a -25.42% decrease from the current price of $14.27. The highest analyst price target is $11.45, and the lowest is $9.8348.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month HQL Price Target
Average 10.50
(-26.39% Downside)
Is Abrdn Life Sciences Investors (HQL) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 61.40 | Neutral |
| STOCH(9,6) | 73.41 | Neutral |
| STOCHRSI(14) | 81.18 | Sell |
| MACD(12,26) | 0.1437 | Buy |
| ADX(14) | 21.43 | Neutral |
| William %R | -15.46 | Sell |
| CCI(14) | 57.48 | Neutral |
Buy: 1
Sell: 2
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
14.15
Buy
|
14.11
Buy
|
| MA20 |
13.86
Buy
|
13.96
Buy
|
| MA50 |
13.82
Buy
|
13.97
Buy
|
| MA100 |
14.38
Sell
|
14.16
Buy
|
| MA200 |
14.39
Sell
|
14.12
Buy
|
Buy: 8
Sell: 2
Neutral: 0
Summary: Buy
According to our latest analysis, HQL could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 4 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on HQL, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 61.4 indicates that HQL is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 73.41 indicates that HQL is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 81.18 indicates that HQL is oversold. This suggests that HQL price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.43 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 57.48 indicates that HQL is still overbought but not to an extreme extent.
Long-term HQL price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Abrdn Life Sciences Investors financial reports and earnings history, Abrdn Life Sciences Investors (HQL) stock could reach $2.9402 by 2030, $9.9732 by 2040 and $29.47 by 2050. See the projected annual prices until 2050 of the Abrdn Life Sciences Investors stock below:
- Abrdn Life Sciences Investors (HQL) is expected to reach an average price of $5.997 in 2035, with a high prediction of $6.0585 and a low estimate of $6.0828. This indicates an $-57.97% rise from the last recorded price of $14.27.
- Abrdn Life Sciences Investors (HQL) stock is projected to chart a bullish course in 2040, with an average price target of $10.08, representing an $-29.34% surge from its current level. The forecast ranges from a conservative $10.10 to a sky-high $9.9732.
- Our analysts predict Abrdn Life Sciences Investors (HQL) to jump 35.14% by 2045, soaring from $19.67 to an average price of $19.28, potentially reaching $20.78. While $19.67 is the low estimate, the potential upside is significant.
- Abrdn Life Sciences Investors (HQL) stock is expected to climb by 2050, reaching an average of $29.82, a $108.95% jump from its current level. However, a wide range of estimates exists, with high and low targets of $29.47 and $29.44, respectively, highlighting the market's uncertainty.
Abrdn Life Sciences Investors Stock (HQL) Year by Year Forecast
Abrdn Life Sciences Investors Stock (HQL) Price Forecast for 2025
Abrdn Life Sciences Investors Stock (HQL) is expected to reach an average price of $10.50 in 2025, with a high prediction of $12.34 and a low estimate of $8.6643. This indicates an -26.39% fall from the last recorded price of $14.27.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $11.33 | $9.8348 | $11.45 | -20.61% |
| April, 2025 | $11.61 | $11.33 | $12.34 | -18.62% |
| May, 2025 | $12.10 | $11.56 | $12.18 | -15.19% |
| June, 2025 | $11.78 | $11.67 | $12.20 | -17.48% |
| July, 2025 | $11.05 | $11.00 | $11.94 | -22.53% |
| August, 2025 | $11.15 | $10.81 | $11.50 | -21.83% |
| September, 2025 | $9.4386 | $8.7891 | $11.63 | -33.86% |
| October, 2025 | $9.5562 | $9.1568 | $9.7972 | -33.03% |
| November, 2025 | $8.8843 | $8.6643 | $9.6553 | -37.74% |
| December, 2025 | $9.182 | $8.7538 | $9.5479 | -35.66% |
Abrdn Life Sciences Investors Stock (HQL) Price Forecast for 2026
The predicted value for Abrdn Life Sciences Investors (HQL) in 2026 is set at an average of $8.7399. Estimates vary from a peak of $10.32 to a trough of $7.163, indicating an -38.75% surge from the present price of $14.27.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $9.2201 | $8.811 | $9.4201 | -35.39% |
| February, 2026 | $8.9182 | $8.8596 | $9.2982 | -37.50% |
| March, 2026 | $8.6563 | $8.6063 | $9.2676 | -39.34% |
| April, 2026 | $8.0839 | $7.9344 | $8.7658 | -43.35% |
| May, 2026 | $8.242 | $7.163 | $8.302 | -42.24% |
| June, 2026 | $7.8301 | $7.5001 | $8.4115 | -45.13% |
| July, 2026 | $9.3878 | $7.7797 | $9.6316 | -34.21% |
| August, 2026 | $9.5959 | $9.3017 | $10.32 | -32.75% |
| September, 2026 | $9.8335 | $9.5454 | $10.21 | -31.09% |
| October, 2026 | $9.5416 | $9.5216 | $10.08 | -33.14% |
| November, 2026 | $9.0997 | $9.0497 | $9.7807 | -36.23% |
| December, 2026 | $8.76 | $8.72 | $9.5639 | -38.61% |
Abrdn Life Sciences Investors Stock (HQL) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Abrdn Life Sciences Investors (HQL) is $6.6823, with a high forecast of $8.2902 and a low forecast of $5.0744. This indicates an -53.17% decrease from the last price of $14.27.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $7.3272 | $6.5386 | $7.3872 | -48.65% |
| February, 2027 | $7.3343 | $6.9301 | $7.5657 | -48.60% |
| March, 2027 | $6.9858 | $6.4615 | $7.4429 | -51.05% |
| April, 2027 | $7.0029 | $6.9201 | $7.3594 | -50.93% |
| May, 2027 | $7.0601 | $6.6415 | $7.2601 | -50.52% |
| June, 2027 | $6.6215 | $6.5415 | $7.1573 | -53.60% |
| July, 2027 | $6.4787 | $6.365 | $6.823 | -54.60% |
| August, 2027 | $5.9859 | $5.8316 | $6.438 | -58.05% |
| September, 2027 | $5.6473 | $5.0744 | $6.3373 | -60.43% |
| October, 2027 | $5.8945 | $5.4402 | $6.0216 | -58.69% |
| November, 2027 | $7.3516 | $5.8988 | $7.5954 | -48.48% |
| December, 2027 | $7.6831 | $7.2703 | $8.2902 | -46.16% |
Abrdn Life Sciences Investors Stock (HQL) Price Forecast for 2028
In 2028, Abrdn Life Sciences Investors (HQL) is projected to reach an average price of $5.7765, with a high projection of $8.2162 and a low estimate of $3.3369. This indicates an -59.52% fall from the last price of $14.27.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $7.8403 | $7.6903 | $8.2162 | -45.06% |
| February, 2028 | $7.5674 | $7.5474 | $8.0895 | -46.97% |
| March, 2028 | $6.9489 | $6.9089 | $7.816 | -51.30% |
| April, 2028 | $6.50 | $6.46 | $7.6278 | -54.45% |
| May, 2028 | $5.0853 | $4.2881 | $5.2553 | -64.36% |
| June, 2028 | $4.9915 | $4.7035 | $5.3343 | -65.02% |
| July, 2028 | $4.7877 | $4.2586 | $5.2305 | -66.45% |
| August, 2028 | $4.533 | $4.5031 | $5.1708 | -68.23% |
| September, 2028 | $4.8292 | $4.472 | $5.1001 | -66.16% |
| October, 2028 | $4.4854 | $4.4054 | $5.0163 | -68.57% |
| November, 2028 | $3.9807 | $3.9707 | $4.6935 | -72.10% |
| December, 2028 | $3.4069 | $3.3369 | $4.2458 | -76.13% |
Abrdn Life Sciences Investors Stock (HQL) Price Forecast for 2029
The 2029 price forecast for Abrdn Life Sciences Investors Stock (HQL) is $4.1506 on average, with a high prediction of $6.2636 and a low estimate of $2.0376. This represents an -70.91% decrease from the previous price of $14.27.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $3.7821 | $2.9859 | $4.2631 | -73.50% |
| February, 2029 | $4.2384 | $3.3803 | $4.2984 | -70.30% |
| March, 2029 | $5.7646 | $4.2674 | $5.8246 | -59.60% |
| April, 2029 | $5.6708 | $5.4817 | $6.2636 | -60.26% |
| May, 2029 | $5.7361 | $5.697 | $6.2229 | -59.80% |
| June, 2029 | $5.6723 | $5.4073 | $6.0541 | -60.25% |
| July, 2029 | $4.9985 | $4.9585 | $5.8513 | -64.97% |
| August, 2029 | $2.2638 | $2.2038 | $5.6917 | -84.14% |
| September, 2029 | $2.8491 | $2.0376 | $3.0191 | -80.03% |
| October, 2029 | $2.7382 | $2.4768 | $3.1029 | -80.81% |
| November, 2029 | $2.6834 | $2.0558 | $2.947 | -81.20% |
| December, 2029 | $2.3587 | $2.3288 | $2.9823 | -83.47% |
Abrdn Life Sciences Investors Stock (HQL) Price Forecast for 2030
Abrdn Life Sciences Investors Stock (HQL) is expected to reach an average price of $2.1442 in 2030, with a high forecast of $4.237 and a low forecast of $0.0514. This signifies an -84.97% decrease from the last price of $14.27.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.5778 | $2.3025 | $2.9402 | -81.94% |
| February, 2030 | $2.3531 | $2.2692 | $2.8754 | -83.51% |
| March, 2030 | $1.8683 | $1.8583 | $2.5669 | -86.91% |
| April, 2030 | $1.3136 | $1.2436 | $2.1478 | -90.79% |
| May, 2030 | $1.7127 | $0.8974 | $2.1889 | -88.00% |
| June, 2030 | $2.1879 | $1.3203 | $2.2479 | -84.67% |
| July, 2030 | $4.027 | $2.2218 | $4.237 | -71.78% |
| August, 2030 | $3.7823 | $3.4647 | $4.0608 | -73.49% |
| September, 2030 | $3.7476 | $3.7038 | $4.2297 | -73.74% |
| October, 2030 | $3.8067 | $3.4378 | $4.0704 | -73.32% |
| November, 2030 | $3.2419 | $3.0081 | $3.8505 | -77.28% |
| December, 2030 | $0.00858 | $0.0514 | $3.7557 | -99.94% |
0.86%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):